CD5 positive B-cell lymphoma (mantle cell lymphoma).
نویسندگان
چکیده
منابع مشابه
CD5- mantle cell lymphoma.
Mantle cell lymphoma (MCL) typically expresses B-cell antigens and CD5 and overexpresses bcl-1 protein. However, unusual cases of bcl-1+ and CD5-MCL have been observed, posing a practical challenge for correct diagnosis and management. We identified 25 cases (48 samples) of bcl-1+ and CD5- lymphoma. CD5 expression was assessed by flow cytometric analysis alone (1 case), immunohistochemical anal...
متن کاملPolymorphism in the CD5 gene promoter in B-cell chronic lymphocytic leukemia and mantle cell lymphoma.
Despite the low incidence of microsatellite instability (MSI) in lymphoid malignant neoplasms, it has been reported that the CD5 promoter MSI was relatively frequent among B-cell chronic lymphoproliferative disorders. We studied the presence of MSI in the CD5 promoter in 134 cases of B-cell chronic lymphocytic leukemia (B-CLL) and 47 of mantle cell lymphoma (MCL) by comparing the pattern of mic...
متن کاملMantle Cell Lymphoma with Multiple Lymphomatous Polyposis Presenting With Intussusceptions
Mantle cell lymphoma is an aggressive type of B-cell non-Hodgkin's lymphoma that originates from small to medium sized lymphocytes located in the mantle zone of the lymph node. The gastrointestinal tract is the predominant site of extranodal involvement in the form of multiple lymphomatous polyposis. Multiple lymphomatous polyposis due to mantle cell lymphoma presenting with intussusception is ...
متن کاملHISTIOCYTE-RICH B-CELL LYMPHOMA: A CASE REPORT OF A RARE VARIANT OF DIFFUSE LARGE B-CELL LYMPHOMA
The authors describe a case of histiocyte-rich B-cell lymphoma (HR-BCL), a variant of diffuse large B-cell lymphoma, in a 51-year-old man. The patient presented with large axillary lymphadenopathy. Histopathologic and immunohistochemical examination of lymph node biopsy revealed diffuse effacement of the lymph node architecture by reactive histiocytes and neoplastic CD20 positive B cells. ...
متن کاملMantle Cell Lymphoma
American Society of Hematology in the first 2 years has also been reduced by 50% in the rituximab-containing treatment arm. These preliminary findings in a pilot study echo the results of previously published studies in advanced disease and provide a lead for future comparative trials. Although the majority of patients with limited disease can be cured using a brief course of doxorubicincontain...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of the Japan Society of the Reticuloendothelial System
سال: 1993
ISSN: 1883-6801,0386-9725
DOI: 10.3960/jslrt1961.33.319